GLP-1 News in Plain English: Children, Dementia, and Insurance Coverage

A short guide to three stories from this month, explained simply

Three stories about GLP-1 medicines got a lot of attention this month. We wrote a full article on each one. This guide gives you the main points in plain language. Each section links to the full article if you want more detail.

1. GLP-1 medicines in young children

The short answer: No GLP-1 medicine is approved to treat obesity in children under 12. Doctors are still prescribing them more often. This is a decision for a pediatrician or a pediatric obesity specialist.

Here is what is approved today. Wegovy (semaglutide) is approved from age 12. Saxenda (liraglutide) is approved for ages 12 to 17 who weigh more than 60 kilograms (about 132 pounds). Zepbound (tirzepatide) is not approved for children at any age. Using any of them under age 12 is off-label or part of a research trial.

What the research shows:

• A trial called SCALE Kids followed 82 children ages 6 to 11 for 56 weeks. Children on liraglutide gained 1.6% in body weight. Children on placebo gained 10%. Nearly half (46%) of the children on the medicine lowered their BMI by at least 5%, compared with 9% on placebo. Stomach side effects were more common on the medicine (80% compared with 54%).
• A study in Pediatrics looked at more than 3.5 million children ages 8 to 11 with obesity. The share getting a GLP-1 each year rose from 0.03% in 2019 to 9.3% in 2026. That is 310 times higher. Among the children who got a GLP-1, 94% had severe obesity. Children in higher-income communities were prescribed these medicines 55% more often.
• Drug companies are now planning or running trials in children as young as 6.

What we do not know yet: how these medicines affect growth, bones, puberty, and muscle over many years. We also do not know what happens when a child stops, or how long treatment should last.

For the full story, read GLP-1 Medications in Young Children. BeLite does not market or provide services to young children.

2. Tirzepatide, semaglutide, and dementia risk

The short answer: A large study looked at people with type 2 diabetes. Those who took tirzepatide or semaglutide had fewer new dementia diagnoses than those who took another type of diabetes medicine. The study cannot prove the medicines caused this. It is not a reason to switch medicines.

The study came from Younis and colleagues and was published in January 2026. They used health records from more than 150 million patients. They looked at adults with type 2 diabetes who did not have dementia at the start. Then they followed them for two years. They compared tirzepatide, semaglutide, and a group of diabetes medicines called SGLT2 inhibitors.

• People on tirzepatide had a 31% lower rate of new dementia diagnoses than people on semaglutide.
• People on tirzepatide had a 34% lower rate than people on SGLT2 inhibitors.
• People on semaglutide had a 29% lower rate than people on SGLT2 inhibitors.

Why we are careful with these results:

• This was not a randomized trial. It looked back at medical records. People who got tirzepatide may have been healthier or more involved in their care to begin with.
• Two years is a short time. Dementia often takes ten years or more to develop.
• Everyone in the study had type 2 diabetes. The results may not apply to people who use these medicines only for weight loss.
• The authors say the findings are a starting point. They say randomized trials are needed before any advice should change.

If you are doing well on your current medicine, there is no reason to switch because of this study. If you have questions, talk with your prescribing doctor. You can also read how the two drugs compare in our tirzepatide and semaglutide head-to-head article. For the full story, read Tirzepatide, Semaglutide, and Dementia Risk.

3. Employers are dropping GLP-1 coverage

The short answer: More employers are ending coverage of GLP-1 medicines for weight loss. Many still cover them for diabetes.

Three surveys this year point the same way:

• A Business Group on Health survey found that 60% of large employers cover GLP-1s for weight loss in 2026 (reported by KFF Health News). That is down from 72% in 2025. Cigna and PwC were reported to have ended coverage. PepsiCo and Starbucks were reported to follow in October 2026.
• In an interview, Employers Health said about 65% of its roughly 500 self-insured clients now exclude GLP-1s for obesity. At the start in 2022 and 2023, about half did.
• A survey from IFEBP found that 60% of employers cover GLP-1s for diabetes only, up from 55% last year. Only 9% of employers that leave out weight-loss coverage are thinking about adding it. GLP-1s now make up 11.4% of employer pharmacy claims, up from 6.9% in 2023.

These surveys count different groups of employers and define coverage in different ways. You cannot add them together or compare them directly. Plans can also change from year to year.

If your coverage ends, do not just stop your medicine. Talk with your prescribing doctor about savings programs, dose options, and paying out of pocket. At BeLite, a first consultation is free whether or not you have insurance. For the full story, read Why More Employers Are Dropping GLP-1 Coverage.